Pharmacokinetics of furosemide in goats following intravenous, intramuscular, and subcutaneous administrations

Gül, Çetin; Çorum, Orhan; Çorum, Duygu Durna; Atik, Orkun; Türk, Erdinç; Tekeli, İbrahim Ozan; Üney, Kamil

doi:10.1111/jvp.13009

Cited by 3 publications

(1 citation statement)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furosemide has a widely ranging bioavailability (10–100%), and different inter- and intra-individual properties are associated with the wide variation for urinary excretion of furosemide (25–42%). On the other hand, torasemide and bumetanide display a more consistent bioavailability that ranges consistently from 80 to 100%, and torasemide has the longest half-life of the loop diuretics (3–4 h) [ 23 , 24 , 25 , 26 ].…”

Section: Loop Diuretic Administration and Application During The Last...mentioning

confidence: 99%

The Changing Role of Loop Diuretics in Heart Failure Management across the Last Century

Palazzuoli,

Mazzeo,

Fortunato

et al. 2024

JCM

View full text Add to dashboard Cite

Congestion is the main therapeutic target of acute heart failure (HF) treatment, and loop diuretics (LDs) are widely used drugs for this purpose. Despite their extensive use, these agents remain largely understudied in terms of modality administration, treatment duration, and escalation dose for subjects responding poorly to therapy. LDs were initially investigated in several edematous statuses such as cirrhosis, nephrotic syndrome, and congestive HF and initially approved for the treatment of cardiogenic congestion in 1966. Despite the long history and the undoubted role in congestion management, the use of LDs in the acute phase is mostly based on the physician’s experience, the oral amount chronically administered, and clinical decongestion response. Recent literature suggests monitoring diuretic activity by the evaluation of daily diuresis, weight loss, and sample urinary sodium assessment after early intravenous LD administration. More recently, the measurement of urinary sodium integrated with urinary and blood creatinine values and fluid status has been suggested as optimal marker to predict whole diuretic efficiency and to target the optimal dose. However, this method is not easily available in the chronic setting or in patients with recurrent hospitalization taking a high loop diuretic amount. Since high loop diuretic dose is related to diuretic resistance (DR) and poorer outcome, additional diuretics acting in different nephron sites are often required. Current sequential nephron blockade can stimulate diuresis by synergic mechanisms. This strategy is attempted in patients with poor response, revealing good results in the early period, but the effects of neuro-endocrine stimulation and electrolyte balance across long-term follow-up are still questioned. This paper reviews the historical course of loop diuretics and highlights the need for a universal approach based on clinical conditions, cardio–renal interactions, and HF phenotypes.

show abstract

Section: Loop Diuretic Administration and Application During The Last...mentioning

confidence: 99%

The Changing Role of Loop Diuretics in Heart Failure Management across the Last Century

Palazzuoli,

Mazzeo,

Fortunato

et al. 2024

JCM

View full text Add to dashboard Cite

show abstract

Hepatocellular carcinoma-associated antigen 59 and ADP-ribosylation factor 1 with poly (lactic-co-glycolic acid): A promising candidate as nanovaccine against haemonchosis

Wang

Muhammad²,

Muhammad³

et al. 2022

Microbial Pathogenesis

View full text Add to dashboard Cite

A novel, small-volume subcutaneous furosemide formulation delivered by an abdominal patch infusor device in patients with heart failure: results of two phase I studies

Osmanska,

Brooksbank,

Docherty

et al. 2023

European Heart Journal - Cardiovascular Pharmacotherapy

View full text Add to dashboard Cite

Aims Subcutaneous (SC) furosemide has potential advantages over intravenous (IV) furosemide by enabling self-administration or administration by a lay caregiver, such as facilitating early-discharge, preventing hospitalizations and in palliative care. A high concentration, pH neutral furosemide formulation has been developed for SC administration via a small patch-infusor pump. We aimed to compare the bioavailability, pharmacokinetic (PK) and pharmacodynamic (PD) profile of a new SC furosemide formulation with conventional IV furosemide, and describe the first use of a bespoke mini-pump to administer this formulation. Methods and Results A novel pH-neutral formulation of SC furosemide containing 80 mg furosemide in ∼2.7 mL (infused over five hours) was investigated. The first study was a PK/PD study of SC furosemide compared to 80 mg IV furosemide administered as a bolus in ambulatory patients with heart failure (HF). The primary outcome was absolute—bioavailability of SC compared to IV furosemide. The second study investigated the same SC furosemide preparation delivered by a patch infusor in patients hospitalized with HF. Primary outcome measures were treatment emergent adverse events, infusion site pain, device performance, and PK measurements. The absolute bioavailability of SC furosemide in comparison to IV furosemide was 112%, resulting in equivalent diuresis and natriuresis. When SC furosemide was administered via the patch pump there were no treatment emergent adverse events and 95% of participants reported no/minor discomfort at the infusion site. Conclusion The novel preparation of SC furosemide had similar bioavailability to IV furosemide. Administration via a patch pump was feasible and well tolerated.

show abstract

Pharmacokinetics of furosemide in goats following intravenous, intramuscular, and subcutaneous administrations

Cited by 3 publications

References 36 publications

The Changing Role of Loop Diuretics in Heart Failure Management across the Last Century

The Changing Role of Loop Diuretics in Heart Failure Management across the Last Century

Hepatocellular carcinoma-associated antigen 59 and ADP-ribosylation factor 1 with poly (lactic-co-glycolic acid): A promising candidate as nanovaccine against haemonchosis

A novel, small-volume subcutaneous furosemide formulation delivered by an abdominal patch infusor device in patients with heart failure: results of two phase I studies

Contact Info

Product

Resources

About